KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology, Molecular Vaccinology and Vaccine Discovery, BE-3000, Leuven, Belgium.
KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy, BE-3000, Leuven, Belgium.
Nat Commun. 2022 Nov 4;13(1):6644. doi: 10.1038/s41467-022-34439-7.
Current COVID-19 vaccines are based on prototypic spike sequences from ancestral 2019 SARS-CoV-2 strains. However, the ongoing pandemic is fueled by variants of concern (VOC) escaping vaccine-mediated protection. Here we demonstrate how immunization in hamsters using prototypic spike expressed from yellow fever 17D (YF17D) as vector blocks ancestral virus (B lineage) and VOC Alpha (B.1.1.7) yet fails to fully protect from Beta (B.1.351). However, the same YF17D vectored vaccine candidate with an evolved antigen induced considerably improved neutralizing antibody responses against VOCs Beta, Gamma (P.1) and the recently predominant Omicron (B.1.1.529), while maintaining immunogenicity against ancestral virus and VOC Delta (B.1.617.2). Thus vaccinated animals resisted challenge by all VOCs, including vigorous high titre exposure to the most difficult to cover Beta, Delta and Omicron variants, eliminating detectable virus and markedly improving lung pathology. Finally, vaccinated hamsters did not transmit Delta variant to non-vaccinated cage mates. Overall, our data illustrate how current first-generation COVID-19 vaccines may need to be updated to maintain efficacy against emerging VOCs and their spread at community level.
当前的 COVID-19 疫苗基于源自 2019 年 SARS-CoV-2 原始刺突序列的原型。然而,正在流行的是逃避疫苗介导保护的关注变体(VOC)。在这里,我们展示了使用黄热 17D(YF17D)作为载体表达的原型刺突在仓鼠中免疫如何阻止原始病毒(B 谱系)和 VOC Alpha(B.1.1.7),但不能完全防止 Beta(B.1.351)。然而,具有进化抗原的相同 YF17D 载体候选疫苗对 VOCs Beta、Gamma(P.1)和最近主要的奥密克戎(B.1.1.529)引起了相当大的改善的中和抗体反应,同时保持对原始病毒和 VOC Delta(B.1.617.2)的免疫原性。因此,接种疫苗的动物抵抗了所有 VOC 的挑战,包括对最难覆盖的 Beta、Delta 和奥密克戎变体的强烈高滴度暴露,消除了可检测的病毒并显著改善了肺部病理学。最后,接种疫苗的仓鼠不会将 Delta 变体传播给未接种疫苗的笼伴。总体而言,我们的数据说明了当前第一代 COVID-19 疫苗可能需要更新,以维持对新兴 VOC 及其在社区层面传播的疗效。